[1] YANG F, MA HP, YOU MR, et al.Applications of Antiviral Drugs in 456 Patients with COVID-19[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(4): 413-416. [2] QIN SL, WANG YT, CAI XJ, et al.Research Progress on Anti-Coronavirus Drugs[J]. Chinese Journal of Comparative Medicine(中国比较医学杂志), 2022, 32(6): 105-110. [3] YIN FH, XI L, SHEN WD, et al.Shen Weisheng’s Experience in Ireventing and Treating Malignant Tumors Based on Concept of “Preventive Treatment of Disease”Theory[J]. Shaanxi Journal of Traditional Chinese Medicine(陕西中医), 2024, 45(10): 1411-1414. [4] MAO JW, YAN WP, LI X, et al.Research Progress of TCM Glycosides in Prevention and Treatment of Intervertebral Disc Degeneration[J]. Asia-Pacific Traditional Medicine(亚太传统医药), 2025, 21(6): 234-239. [5] ZHAO XL.Discussion on Aromatic TCM Medicines in the Prevention and Treatment of COVID-19[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2023, 15(12): 90-94. [6] YAN YF, ZHANG XW, SONG YP.From Qingjie Fanggan Granules to Discuss TCM Preventive Treatment of Disease[J]. Journal of Shaanxi University of Chinese Medicine(陕西中医药大学学报), 2017(1): 10-12. [7] WU M, YANG R, SHEN X, et al.Influence of Qingjie Fanggan Particles on Immune Function of Low Immunity Mice Induced by Cyclophosphamide[J]. Journal of Liaoning University of TCM(辽宁中医药大学学报), 2013, 15(2): 53-54. [8] SONG YP, WANG XY. XUE JD, et al.Clinical Observation on Prevention of Influenza A(H1N1) by Qingjie Fanggan Granule[J]. Shaanxi Journal of Traditional Chinese Medicine(陕西中医), 2019, 40(7): 886-889. [9] GAO K, SONG YP, DU X, et al.Exploring Multiple Mechanisms of Qingjie Fanggan Prescription for Prevention and Treatment of Influenza Based on Systems Pharmacology[J]. Comput Biol Chem, 2020, 88: 107307. [10] ZHANG Y, LU Y, LUO M, et al.Based on Treatise on Febrile Diseases, Syndrome Differentiation and Treatment of Current COVID-19 Infection from the Six Meridians Syndrome Differen- tiation[J]. Journal of Sichuan of Traditional Chinese Medicine(四川中医), 2024, 42(2): 74-76. [11] FU JZ, DONG JL.Renew Popular Treatise on Cold Pathogenic Diseases and Treatment of A (H1N1) Influenza[J]. China Journal of Traditional Chinese Medicine(中华中医药杂志), 2011, 26(2): 223-224. [12] MIAO Q, CONG XD, WANG B, et al.TCM Understanding and Reflection on COVID-19[J]. Journal of Traditional Chinese Medicine(中医杂志), 2020, 61(4): 286-288. [13] LIU LT, LI J, PENG GY, et al.Analysis of the Similarities and Differences among Severe Acute Respiratory Syndrome, Influenza A H1N1 and Corona Virus Disease 2019 Based on the Theory of TCM[J]. Journal of LiaoNing University of TCM(辽宁中医药大学学报), 2021, 23(1): 208-212. [14] ZHANG JS, ZHAO RH, ZHANG W, et al.Pharmacological Effect Study of Yiye Anti-Influenza Capsule on Mice with Damp-Heat Epidemic Toxin Attacking Lung Induced by Human Coronavirus 229E[J]. Chinese Journal of Virology(病毒学报), 2024, 40(2): 233-240. [15] SUN QY, GUO SS, GAO SR, et al. Preliminary Proteomics-Based Investigation of Therapeutic Effect and Mechanism of Verbenalin on Coronavirus HCoV-229E[J/OL]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), (2025-06-13)[2025-09-08]. https://doi.org/10.13422/j.cnki.syfjx.20251240. [16] XU YL.Construction and Application of Human Virus 229E (HCoV-229E) Pneumonia Model in Mouse[D]. Beijing: China Academy of Chinese Medical Sciences, 2022. [17] ZHANG JS, GAO SR, PANG B, et al.The Mechanism of Sanhan Huashi Granules on Pneumonia Induced by Human Coronavirus 229E and OC43 in Mice[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(1): 51-54,88. [18] SALEEM S.Targeting MAPK Signaling: a Promising Approach for Treating Inflammatory Lung Disease[J]. Pathol Res Pract, 2024, 254: 155122. [19] KIM EK, CHOI EJ.Pathological Roles of MAPK Signaling Pathways in Human Diseases[J]. Biochim Biophys Acta, 2010, 1802(4): 396-405. [20] WANG L, XIA Z, TANG W, et al.p38 Activation and Viral Infection[J]. Expert Rev Mol Med, 2022, 24: e4. [21] PADHAN K, MINAKSHI R, TOWHEED MAB, et al.Severe Acute Respiratory Syndrome Coronavirus 3a Protein Activates the Mitochondrial Death Pathway through p38 MAP Kinase Activation[J]. J Gen Virol, 2008, 89(Pt 8): 1960-1969. [22] GRIMES JM, GRIMES KV. p38 MAPK Inhibition: a Promising Therapeutic Approach for COVID-19[J]. J Mol Cell Cardiol, 2020, 144: 63-65. [23] MARCHANT D, SINGHERA GK, UTOKAPARCH S, et al.Toll-Like Receptor 4-Mediated Activation of p38 Mitogen-Activated Protein Kinase is a Determinant of Respiratory Virus Entry and Tropism[J]. J Virol, 2010, 84(21): 11359-11373. |